Last reviewed · How we verify

Cholera — Treatment Landscape & Competitive Intelligence

Cholera (disease) competitive landscape: 4 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

4 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Cholera, deduplicated by molecule. See the full disease page for line-of-therapy detail.

DrugGenericSponsorClassTargetLine of therapyFirst approval
Minocycline Hydrochloride MINOCYCLINE Rempex Tetracycline-class Drug 1971-01-01
Vibramycin doxycycline Generic (originally Pfizer) Tetracycline antibiotic 72 kDa type IV collagenase, Stromelysin-1, Collagenase 3 1967-01-01
Doxycyclin Doxycyclin Bulovka Hospital 72 kDa type IV collagenase, Stromelysin-1, Collagenase 3
Minocyclin Minocyclin University of Southern California 30S ribosomal protein S4, 30S ribosomal protein S9, Tetracycline resistance protein, class B

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

  1. · 1 drug in Cholera
  2. Bulovka Hospital · 1 drug in Cholera
  3. Generic (originally Pfizer) · 1 drug in Cholera
  4. Rempex · 1 drug in Cholera
  5. University of Southern California · 1 drug in Cholera

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Cholera:

Cite this brief

Drug Landscape (2026). Cholera — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/cholera. Accessed 2026-06-10.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing